COMMUNIQUÉS West-GlobeNewswire

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
16/04/2026
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative [...]
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
16/04/2026
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today [...]
Blood Cancer Patients and Their Supporters Cycle Across Iceland to Raise Funds and Awareness for Multiple Myeloma and the International Myeloma Foundation’s Research
16/04/2026
3rd Annual Iceland Cycling Expedition from August 18-24, 2026, Aims to Fund Myeloma Prevention and a Cure STUDIO CITY, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today [...]
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
16/04/2026
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. BOSTON, April 16, 2026 ( [...]
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
16/04/2026
Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 ( [...]
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
16/04/2026
American Society of Gene and Cell Therapy 29 th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference 3 rd International Conference on Ureagenesis Defects and Allied Conditions [...]
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
16/04/2026
TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
16/04/2026
Company to participate in Live Virtual Investor Closing Bell segment today, April 16 th  at 4:00 PM ET ; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: [...]
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
16/04/2026
Reimbursement for Office-Based Utilization to Begin in July 2026 NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America [...]
Elicio Therapeutics Reports Inducement Grants
16/04/2026
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of [...]
Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros
16/04/2026
Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros Lille, 16 April, 2026 – Roquette, a global leader of plant-based ingredients and pharmaceutical excipients for the health and [...]
Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
16/04/2026
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑ [...]
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
16/04/2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with [...]
CancerVax to Target Colorectal Cancer Following Recent Biodistribution Breakthroughs
16/04/2026
New findings support hypothesis that current nanoparticle designed for pancreatic and liver cancers could also work for colorectal cancer Lehi, Utah, April 16, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of [...]
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
16/04/2026
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up [...]
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros
16/04/2026
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros Lille, le 16 avril 2026 - Roquette, un leader mondial des ingrédients d'origine végétale et un fournisseur majeur d’ [...]
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
16/04/2026
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First ‑ in ‑ class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation CAMBRIDGE, [...]
Eurobio scientific signs definitive agreement to acquire CareDx’s transplant Lab Product division
16/04/2026
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing [...]
Pharming Group announces the 2026 Annual General Meeting of Shareholders
16/04/2026
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “ [...]

Pages